Pharmacokinetics and pharmacodynamics of tonapofylline in subjects with severe renal impairment and in elderly subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 9, 2011, Pages 563-570

  Li, Z ^a,d   TenHoor, C ^a,e   Marbury, T ^b   Swan, S ^c   Zhu, Y ^a   Ticho, B ^a  

^a BIOGEN   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

^c UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^d GENZYME CORPORATION   (United States)

^e Dyax Corp   (United States)

Author keywords

Elderly; Pharmacodynamics; Pharmacokinetics; Renal impairment; Tonapofylline

Indexed keywords

SODIUM; TONAPOFYLLINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIURETIC ACTIVITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FEMALE; HUMAN; KALIURESIS; KIDNEY CLEARANCE; KIDNEY FAILURE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM EXCRETION; SODIUM URINE LEVEL; UREA CLEARANCE; URINE VOLUME;

ADENOSINE A1 RECEPTOR ANTAGONISTS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; XANTHINES;

EID: 80053032054     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201518     Document Type: Article

References (24)

1. Ensor CR, Russell SD. Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure. Expert Opin Pharmacother. 2010; 11: 2405-2415. doi:10.1517/14656566.2010.5 14605 PubMed
2. Gottlieb SS, Ticho B, Deykin A et al. Effects of BG9928, an adenosine Al receptor antagonist, in patients with congestive heart failure. J Clin Pharmacol. 2010: (published online ahead of print, October 06, 2010).
3. Kiesman WF, Elzein E, Zablocki J. A1 adenosine receptor antagonists, agonists, and allosteric enhancers. Handb Exp Pharmacol. 2009; 193: 25-58. doi:10.1007/978-3-540-89615-92 PubMed
4. Greenberg B, Thomas I, Banish D, Goldman S, Havranek E, Massie BM, Zhu Y, Ticho B, Abraham WT. Effects of multiple oral doses of an A1 adenosine antagonist; BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study. J Am Coll Cardiol. 2007; 50: 600-606. doi:10.1016/j.jacc.2007.03.059 PubMed
5. Sun D, Samuelson LC, Yang T, Huang Y, Paliege A, Saunders T, Briggs J, Schnermann J. Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci USA. 2001; 98:9983-9988. doi: 10.1073/pnas.171317998 PubMed (Pubitemid 32769414)
6. Ren Y, Garvin JL, Carretero OA. Efferent arteriole tubuloglomerular feedback in the renal nephron. Kidney Int. 2001; 59: 222-229. doi:10.1046/j.1523-1755.2001.00482.x PubMed (Pubitemid 32055229)
7. Mitrovic V, Seferovic P, Dodic S, Krotin M, Neskovic A, Dickstein K, De Voogd H, Böcker C, Ziegler D, Godes M, Nakov R, Essers H, Verboom C, Hocher B. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure. Circ Heart Fail. 2009; 2: 523-531. doi:10.1161/CIRCHEARTFAILURE.108.798389 PubMed
8. Ticho B, Whalley E, Gill A, Lutterodt F, Jin X, Auchampach J, Smits G. Renal Effects of BG9928, an A1 adenosine receptor antagonist, in rats and nonhuman primates. Drug Dev Res. 2003; 58: 486-492. doi:10.1002/ddr.10176 (Pubitemid 36676351)
9. Gill A, Wortham K, Costa D, Davis W, Ticho B, Whalley E. Protective effect of tonapofylline (BG9928), an adenosine A1 receptor antagonist, against cisplatin-induced acute kidney injury in rats. Am J Neplsrol. 2009; 30: 521-526. doi.10.1159/000248762 PubMed
10. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systoLic dysfunction. J Am Coll Cardiol. 2000; 35: 681-689. doi:10.1016/S0735-1097(99)00608-7 PubMed (Pubitemid 30167025)
11. Fonarow GC; ADHERE Scientific Advisory Committee. The Acute Decompenaated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovaac Med. 2003; 4(Suppl 7): S21-S30.PubMed
12. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. Eu roHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: descrip tion of population. Eur Heart J. 2006; 27: 2725- 2736. doi:10.1093/eurheartj/eh1193 PubMed
13. Nessler J, Skrzypek A. Chronic heart failure in the elderly: a current medical problem. Pol Arch Med Wewn. 2008; 118. 572-580. PubMed
14. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics -2010 update: a re port from the American Heart Association Statis tics Committee and Stroke Statistics Subcommit tee. Circulation. 2010; 121: e1-e170. PubMed
15. Jugdutt BI. Aging and heart failure: changing de mographics and implications for therapy in the eLderly. Heart Fail Rev. 2010; 15: 401-405. doi:10.1007/s10741-010-9164-8 PubMed
16. McMurray JJ, Stewart S. Epidemiology, aetiolo gy, and prognosis of heart failure. Heart. 2000; 83: 596-602. doi:10.1136/heart.83.5.596 PubMed (Pubitemid 30316742)
17. Mender GF, Cowie MR. The epidemiological fea tures of heart failure in developing countries: a re view of the literature. Int J Cardiol. 2001; 80: 213- 219. doi: 10.1016/S0167-5273(01)00497-1 PubMed
18. Jugdutt BI. Heart failure in the elderly: advances and challenges. Expert Rev Cardiovasc Ther. 2010; 8:695-715. doi:10.1586/erc.10.36 PubMed
19. Food and Drug Administration/Center for Drug Evaluation and Research (CDER). Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. March2003.
20. Steinijans VW, Hartmann M, Huber R, Radtke HW. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol. 1991; 29: 323-328. PubMed
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999; 130: 461-470. PubMed (Pubitemid 29135798)
22. Li Z, TenHoor C, Marbury T et al. Clinical phar macokinetics of tonapofylline: evaluation of dose proportionality, oral bioavailability, gender and food effects in healthy human subjects. J Clin Pharmacol. 2010 (published online ahead of print, October 06, 2010).
23. Prakash C, Yang L, Li Z, Gan L, Klunk L. Species and gender related differences inthemetabolisin of a potent adenosine A1 receptor antagonist tonapofylline, in rats and monkeys. Drug Metab Rev. 2010; 42 (S1). 97.
24. Li Z, Yang L, Gan L, Klunk L, Deykin A, Prakash C. Pharmacokinetics metabolism and excretion of an ade nosine A1 receptor antagonist, tonapofylline, in healthy human subjects. Drug Metab Rev. 2010; 42 (S1). 95.